Table 1.
Characterization parameters of MSNs, MSNs-DM1, MSNs-DM1@PDA-PEG, and MSNs-DOX@PDA-PEG-APt
| Sample | Sizea (nm) | ZP (mV) | BET surface area (m2/g) | Pore volumeb (cm3/g) | Pore sizec (nm) |
|---|---|---|---|---|---|
| MSNs | 137.34±6.75 | −19.22±3.26 | 257.36 | 0.58 | 2.65 |
| MSNs-DM1 | 148.45±5.64 | −7.65±4.23 | 125.25 | 0.41 | 2.23 |
| MSNs-DM1@PDA-PEG | 189.43±4.65 | −26.77±4.56 | 50.58 | 0.14 | – |
| MSNs-DM1@PDA-PEG-APt | 203.75±2.37 | −10.84±5.43 | 52.78 | 0.12 | – |
Notes:
a
NPs size was measured by dynamic light scattering. Data are expressed as mean ± SD.
b
BJH cumulative pore volume for pores between 1.7 and 300 nm in width.
c
Most probable pore size. ‘–’ indicates pore not detected.
Abbreviations: NPs, nanoparticles; SD, standard deviation; BJH, Barrett–Joyner–Halenda; MSNs, mesoporous silica nanoparticles; PDA, hydrochloride dopamine; PEG, polyethylene glycol; APt, aptamer; ZP, zeta potential; BET, Brunauer–Emmett–Teller; DOX, doxorubicin.